Dr. Pierre Sicard obtained from the University of Burgundy, a PhD in Cardiovascular physiology (under the supervision of Pr ROCHETTE) in October 2007. During his PhD, he studied the interplay between oxidative stress, hypertension and their consequences on the heart. He published four publications from his PhD work in peer review journals (e.g. British Journal of Pharmacology, American journal of hypertension) and he has confirmed the major importance of oxidative stress during cardiovascular pathology. He has also accumulated three years of experience in clinical research in cardiology, which has given him the opportunity to work closely with cardiologists, biologists and bioengineers.

In November 2007, he joined Michael MARBER’s group at King’s College London for his first postdoctoral position. His aim was to study the importance of p38 MAPK isoforms during myocardial infarction. In addition, he discovered a new biomarker (MYBP-c) for the early detection of myocardial infarction in patients.

In 2011, Dr. Sicard obtained 3 grants from different French research foundations (310Keuros) and took the opportunity to develop his own project at the Institute of Metabolic and Cardiovascular Diseases in Toulouse, France. The aim of this bench to bedside study was to determine the potential contribution of Gadd45 proteins in post-infarction remodeling. To do so, he developed several specific experimental models (e.g. adult cardiomyocytes isolation and culture, Langendorff perfusion, PV-loop analysis, echocardiography and speckle tracking using the Vevo 2100, in an in vivo model of myocardial infarction in mice.

Since 2016, Dr. Sicard has held a permanent position at INSERM Montpellier (PhyMedExp Lab) as a research engineer. He oversees the ultrasound/photoacoustic facility (Vevo LAZR-X) and obtained a Habilitation à Diriger des Recherche in 2024.